Overview
Arpico Insurance is a Sri Lankan life and health insurer, serving individual and corporate customers through its distribution network and digital service infrastructure. The central change is a sharply weakened earnings base: the latest audited year almost eliminated profit, and the September quarter remained loss-making even though the loss was smaller than a year earlier.
Price performance
The share closed at LKR 24.80 on 13 November 2026 after falling 35.1% over one year, against a 4.7% fall in the ASPI. It sat 13.5% up its 52-week range, placing it close to the year's low rather than near its peak.
The three-year record includes several substantial retreats, with the deepest reaching 42% and not yet recovering. Liquidity is exceptionally limited: a LKR 1 million order is more than everything that trades on a typical day (10496% of it), making that size a very large part of normal trading.
Valuation
The valuation is split between book value and earnings. At 207 times P/E, the market price represents 207 rupees for every rupee of trailing profit, and is the highest P/E among the nine insurance peers with usable earnings multiples. That multiple reflects a trailing EPS base of only LKR 0.12, so the valuation rests on very little reported profit.
P/B is more restrained at 0.96 times, meaning the shares cost 96 cents for each rupee of net assets, versus the sector median of 1.51 times. It ranks in the cheaper fifth of the sector on P/B and is "cheaper than 50% of days since March 2015". The latest audited return on equity was only 0.5%, however, so the below-book valuation is consistent with weak earnings on those assets. No dividend is on record in the last two years.
News and sentiment
There were no material company articles in the latest 90-day news window. Earlier reports in June and July covered the 2025 profit disclosure and routine Board and audit committee appointments, without disclosing a new earnings-sized operating development.
Financials
September-quarter revenue fell 16.5% year-on-year to LKR 416.9 million, while the net loss narrowed by LKR 9.5 million to LKR 0.8 million. Gross margin is unavailable for both September comparisons, and operating margin is unavailable for September 2026, preventing a like-for-like operating-margin assessment. Net margin improved to -0.2% from -2.0% a year earlier: the insurer still lost money, but only around a fifth of a cent on each rupee of revenue rather than two cents.
That net margin was middling among the company's eight September quarters on record, ranking sixth. The result therefore narrowed a loss but did not establish a strong quarter against its own comparable September history.
The latest audited year ended December 2025 was much weaker, with net profit down 96.6% and return on equity at 0.5%. Equity at September was LKR 1.7 billion, down from LKR 2.0 billion a year earlier, while the ordinary share count remained 66.2 million; the weaker per-share outcome is therefore not the mechanical result of a share-count increase.
Risks
The main financial risk is the insurer's higher balance-sheet leverage. Total liabilities were 2.22 times equity at the latest audited year, up from 1.72 times a year earlier, meaning the company had LKR 2.22 of obligations, including insurance liabilities, for each rupee of equity supporting them.
The earnings risk is equally material: audited profit fell 96.6%, and the latest quarter still made a loss. For an insurer, falling bond yields can affect investment portfolio valuations and reinvestment income; this is sector context as at 13 November 2026, not evidence of a company-specific effect. The very thin share turnover is a separate practical risk for building or exiting a position.
Outlook
As at 13 November 2026, the next material event is the audited year-end filing for 31 December 2026, expected between 28 April and 3 June 2027. It will show whether the weak 2025 earnings base and September loss persisted or whether underwriting and investment income restored profitability.
The available data cannot separate the causes of the revenue contraction or quantify the contribution from the insurer's investment portfolio. Until the annual filing, the reported record supports a narrowed quarterly loss, but not a demonstrated earnings recovery.